In its new guidance (PDF), health technology assessment (HTA) agency NICE notes that, at the moment, patients with chronic ITP who do not respond to or cannot tolerate TPO-RA drugs are treated ...

This drug works by reducing both the destruction ... to avatrombopag, a newer oral TPO-RA. The results were promising, with a high response rate observed in patients who had previously not ...

Three principal thyroid autoantigens are involved in AITD. These are thyroperoxidase (TPO), thyroglobulin (Tg) and the TSH receptor. Other autoantigens, such as the Sodium Iodide Symporter (NIS ...

The US Food and Drug Administration (FDA ... is a thrombopoietin receptor agonist (TPO-RA) that does not compete with thrombopoietin (TPO) for receptor binding. It functions by stimulating ...